Unexpected low-level viremia among HIV-infected Ugandan adults with untreated active tuberculosis

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 4, 2008, Pages 458-460

  Srikantiah, Padmini ^a   Wong, Joseph K ^a,b   Liegler, Teri ^a   Walusimbi, Maria ^c   Mayanja Kizza, Harriet ^c   Kayanja, Harriet K ^d   Mugerwa, Roy D ^c   Charlebois, Edwin D ^e   Boom, W Henry ^d   Whalen, Christopher C ^d   Havlir, Diane V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PREDNISOLONE; TUBERCULOSTATIC AGENT; VIRUS RNA;

ATTENUATION; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; COMPARATIVE STUDY; DEMOGRAPHY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LUNG TUBERCULOSIS; MEASLES VIRUS; MYCOBACTERIUM TUBERCULOSIS; ORIENTIA TSUTSUGAMUSHI; PATIENT CODING; PRIORITY JOURNAL; RNA ANALYSIS; UGANDA; VIREMIA; VIRUS LOAD; WESTERN BLOTTING;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; RNA, VIRAL; TUBERCULOSIS, PULMONARY; UGANDA; VIRAL LOAD; VIREMIA;

EID: 57649123365     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31817e9fb4     Document Type: Letter

References (17)

1. Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS. 2002;16:75-83.
2. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. 1996;157:1271-1278.
3. Toossi Z. Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis. 2003;188:1146-1155.
4. Mayanja-Kizza H, Jones-Lopez E, Okwera A, et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J Infect Dis. 2005;191:856-865.
5. Srikantiah P, Walusimbi M, Kayanja H, et al. Safety and early virologic response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis (TB) in Uganda. AIDS. 2007;21:1971-1974.
6. Centers for Disease Control and Prevention. Treatment of tuberculosis. MMWR Morb Mortal Wkly Rep. 2003;52:1-77.
7. Michael NL, Herman SA, Kwok S, et al. Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J Clin Microbiol. 1999;37:2557-2563.
8. Herbeck JT, Lyagoba F, Moore SW, et al. Prevalence and genetic diversity of HIV type 1 subtypes A and D in women attending antenatal clinics in Uganda. AIDS Res Hum Retroviruses. 2007;23:755-760.
9. Falk A, O'Connor JB, Pratt C. Classification of Pulmonary Tuberculosis: Diagnostic Standards and Classification of Tuberculosis. New York, NY: National Tuberculosis and Respiratory Disease Association; 1969.
10. Morris L, Martin DJ, Bredell H, et al. Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J Infect Dis. 2003;187:1967-1971.
11. Toossi Z, Mayanja-Kizza H, Hirsch CS, et al. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol. 2001;123:233-238.
12. Kublin JG, Patnaik P, Jere CS, et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet. 2005;365:233-240.
13. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol. 2005;34:215-220.
14. Kannangara S, DeSimone JA, Pomerantz RJ. Attenuation of HIV-1 infection by other microbial agents. J Infect Dis. 2005;192:1003-1009.
15. Goletti D, Carrara S, Vincenti D, et al. Inhibition of HIV-1 replication in monocyte-derived macrophages by Mycobacterium tuberculosis. J Infect Dis. 2004;189:624-633.
16. Orenstein JM, Fox C, Wahl SM. Macrophages as a source of HIV during opportunistic infections. Science. 1997;276:1857-1861.
17. Guyot-Revol V, Innes JA, Hackforth S, et al. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. Am J Respir Crit Care Med. 2006;173:803-810.